Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Should You Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares saw strong trading volume on Monday . 125,979 shares were traded during mid-day trading, an increase of 142% from the previous session’s volume of 51,989 shares.The stock last traded at $27.24 and had previously closed at $26.40.

Chugai Pharmaceutical Stock Up 2.9%

The stock has a market capitalization of $89.38 billion, a price-to-earnings ratio of 33.95 and a beta of 0.63. The business’s 50-day moving average is $25.71 and its two-hundred day moving average is $24.13.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, October 24th. The company reported $0.23 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%.The business had revenue of $2.26 billion for the quarter. As a group, analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.